Neuraxis (NRXS) Other Non-Current Assets (2024 - 2026)
Neuraxis (NRXS) posted Other Non-Current Assets of $20163.0 for Q1 2026, down 15.51% sequentially from $23864.0 in Q4 2025, and little changed YoY from $20163.0 in Q1 2025.
Neuraxis (NRXS) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Neuraxis has reported Other Non-Current Assets for 3 years, with the latest figure at $20163.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $20163.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20163.0 (changed 0.0% YoY) and the FY2025 annual result came in at $23864.0, up 18.36% from the prior year.
- Other Non-Current Assets retreated to $20163.0 in Q1 2026 per NRXS's latest filing, from $23864.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $23864.0 in Q4 2025 and troughed at $20163.0 in Q3 2024.
- A 3-year average of $20691.7 and a median of $20163.0 in 2024 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 18.36% in 2025, down 0.0% in 2025.
- Over 3 years, Other Non-Current Assets stood at $20163.0 in 2024, then advanced by 18.36% to $23864.0 in 2025, then dropped by 15.51% to $20163.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $20163.0, $23864.0, and $20163.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | 29,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29,793.00 |
| Mar 31, 2026 | 20,163.00 |
| Dec 31, 2025 | 23,864.00 |
| Sep 30, 2025 | 20,163.00 |
| Jun 30, 2025 | 20,163.00 |
| Mar 31, 2025 | 20,163.00 |
| Dec 31, 2024 | 20,163.00 |
| Sep 30, 2024 | 20,163.00 |